Cargando…
Compensatory intestinal immunoglobulin response after vancomycin treatment in humans
Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is re...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833805/ https://www.ncbi.nlm.nih.gov/pubmed/33475461 http://dx.doi.org/10.1080/19490976.2021.1875109 |
_version_ | 1783642146238103552 |
---|---|
author | Scheithauer, Torsten P. M. Bakker, Guido J. Winkelmeijer, Maaike Davids, Mark Nieuwdorp, Max van Raalte, Daniël H. Herrema, Hilde |
author_facet | Scheithauer, Torsten P. M. Bakker, Guido J. Winkelmeijer, Maaike Davids, Mark Nieuwdorp, Max van Raalte, Daniël H. Herrema, Hilde |
author_sort | Scheithauer, Torsten P. M. |
collection | PubMed |
description | Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is regulated by alterations in gut microbiome composition, an event rarely mapped in an intervention setting in humans. Here, we determined the intestinal and systemic Ig response to a major intervention in gut microbiome composition. Healthy humans and humans with metabolic syndrome received oral vancomycin 500 mg four times per day for 7 days. Coinciding with a vancomycin-induced increase in Gram-negative bacteria, fecal levels of the immunogenic bacterial components lipopolysaccharide (LPS) and flagellin drastically increased. Intestinal antibodies (IgA and IgM) significantly increased, whereas peripheral antibodies (IgG, IgA, and IgM) were mostly unaffected by vancomycin treatment. Bacterial cell sorting followed by 16S rRNA sequencing revealed that the majority of Gram-negative bacteria, including opportunistic pathogens, were IgA-coated after the intervention. We suggest that the intestinal Ig response after vancomycin treatment prevents the intrusion of pathogens and bacterial components into systemic sites. |
format | Online Article Text |
id | pubmed-7833805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-78338052021-02-02 Compensatory intestinal immunoglobulin response after vancomycin treatment in humans Scheithauer, Torsten P. M. Bakker, Guido J. Winkelmeijer, Maaike Davids, Mark Nieuwdorp, Max van Raalte, Daniël H. Herrema, Hilde Gut Microbes Research Paper Intestinal immunoglobulins (Ig) are abundantly secreted antibodies that bind bacteria and bacterial components in the gut. This binding is considered to accelerate bacterial transit time and prevent the interaction of potentially immunogenic compounds with intestinal immune cells. Ig secretion is regulated by alterations in gut microbiome composition, an event rarely mapped in an intervention setting in humans. Here, we determined the intestinal and systemic Ig response to a major intervention in gut microbiome composition. Healthy humans and humans with metabolic syndrome received oral vancomycin 500 mg four times per day for 7 days. Coinciding with a vancomycin-induced increase in Gram-negative bacteria, fecal levels of the immunogenic bacterial components lipopolysaccharide (LPS) and flagellin drastically increased. Intestinal antibodies (IgA and IgM) significantly increased, whereas peripheral antibodies (IgG, IgA, and IgM) were mostly unaffected by vancomycin treatment. Bacterial cell sorting followed by 16S rRNA sequencing revealed that the majority of Gram-negative bacteria, including opportunistic pathogens, were IgA-coated after the intervention. We suggest that the intestinal Ig response after vancomycin treatment prevents the intrusion of pathogens and bacterial components into systemic sites. Taylor & Francis 2021-01-21 /pmc/articles/PMC7833805/ /pubmed/33475461 http://dx.doi.org/10.1080/19490976.2021.1875109 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Scheithauer, Torsten P. M. Bakker, Guido J. Winkelmeijer, Maaike Davids, Mark Nieuwdorp, Max van Raalte, Daniël H. Herrema, Hilde Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title | Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title_full | Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title_fullStr | Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title_full_unstemmed | Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title_short | Compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
title_sort | compensatory intestinal immunoglobulin response after vancomycin treatment in humans |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833805/ https://www.ncbi.nlm.nih.gov/pubmed/33475461 http://dx.doi.org/10.1080/19490976.2021.1875109 |
work_keys_str_mv | AT scheithauertorstenpm compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT bakkerguidoj compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT winkelmeijermaaike compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT davidsmark compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT nieuwdorpmax compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT vanraaltedanielh compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans AT herremahilde compensatoryintestinalimmunoglobulinresponseaftervancomycintreatmentinhumans |